Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical company AstraZeneca posted a 22% fall in annual profit after rising revenue was offset by an increase in selling and other administrative costs.
Pre-tax profit for the year through December fell to $1.55bn, down from $1.99bn on-year.
Revenue rose 10% to $24.4bn, though operating profit fell 14% to $2.92bn.
AstraZeneca said its 'core' operating profit, which excludes certain expenses, rose 13% to $6.44bn.
Looking ahead, it said, depending on the impact of the coronavirus outbreak, its revenue was expected to increase by a high single-digit to a low double-digit percentage in 2020.
Core earnings per share were expected to increase by a mid- to high-teens percentage. In 2019, core EPS rose 1% to $3.50.
'In the first full year of our return to growth, we made good progress in line with our strategy,' chief executive Pascal Soriot said.
Soriot said the company was becoming a better-balanced business, both regionally and through its medicines.
'This transition is a further step towards improving operating leverage and cash generation,' he said.
'As we accelerate our commitments to achieving our long-term climate-change and decarbonisation targets, we will maintain our focus on executing a strategy centred on science and patients.'